Table 4 Comparison of clinical outcomes between autoantibody-negative patients and ANA, IgM aβ2-GPI, IgG aCL, and IgM aCL/IgM aβ2-GPI patients
From: Prevalence, clinical significance, and persistence of autoantibodies in COVID-19
Control group (n = 202) | ANA (n = 5) | IgM aβ2-GPI (n = 26) | IgG aCL (n = 6) | IgM aCL/IgM aβ2-GPI (n = 5) | P | P` | P`` | P``` | |
|---|---|---|---|---|---|---|---|---|---|
In-hospital mortality, No. | 51 (25.2) | 1 (20.0) | 5 (19.2) | 4 (66.7) | 0 | > 0.99 | 0.668 | 0.072 | 0.442 |
Thromboembolism, No. | 13 (6.4) | 0 | 2 (7.7) | 2 (33.3) | 0 | > 0.99 | > 0.99 | 0.087 | > 0.99 |
Mechanical ventilation, No. | 82 (40.6) | 0 | 11 (42.3) | 5 (83.3) | 3 (60.0) | 0.171 | > 0.99 | 0.095 | 0.681 |
ECMO support, No. | 6 (3.0) | 0 | 1 (3.8) | 0 | 0 | > 0.99 | > 0.99 | > 0.99 | > 0.99 |
CRRT, No. | 12 (5.9) | 0 | 1 (3.8) | 2 (33.3) | 0 | > 0.99 | > 0.99 | 0.07 | > 0.99 |
Length of stay, median, d | 18.0 (13.0–30.0) | 13.0 (12.0–17.0) | 18.0 (13.0–25.0) | 2.0 (22.0–28.0) | 14.0 (13.0–21.0) | 0.13 | 0.694 | 0.426 | 0.412 |